Other News

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO): “During our fiscal third quarter, we took another significant step in our transformation with the divestiture of our PICC and Midline product portfolios, further strengthening our balance sheet and providing us with an opportunity to enhance our focus on the growth of our Med […]

AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the United States Food and Drug Administration (FDA) has cleared the AlphaVac F1885 System for […]

Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre

CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces a strategic partnership with Navierre, an innovative digital health technology platform which revolutionizes how patients access healthcare and serves as a true health companion for every stage from birth to the golden years with a robust care […]

Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.24

Clinical and real-world evidence presentations highlight how the Company is transforming care for patients who are fighting some of the most common and devastating cardiovascular diseases NEW BRUNSWICK, N.J., April 4, 2024 /PRNewswire/ — Johnson & Johnson announced today that clinical…

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to two newly hired employees. These grants were made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and were made as an inducement material to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Viz.ai® Announces Three New Studies Supporting Viz HCM™ Module for the Detection and Management of Suspected Hypertrophic Cardiomyopathy

April 03, 2024 08:00 AM Eastern Daylight Time SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care. Three studies, presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo 2024, have shown positive […]

GE HealthCare Introduces Caption AI on Vscan Air SL Wireless Handheld Ultrasound System to Help More Clinicians Capture Diagnostic-Quality Cardiac Images

April 03, 2024 08:00 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–GE HealthCare (Nasdaq: GEHC) today announced the launch of Caption AI artificial intelligence (AI)-driven software for rapid cardiac assessments at the point of care on Vscan Air SL. Now, with Caption AI technology, clinicians using Vscan Air SL handheld ultrasound will […]